Vimarsana
Biggest News Aggregation in the World

Page 49 - Medication Guide News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Medication Guide. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Medication Guide Today - Breaking & Trending Today

FDA Approves Genentech's Polivy in Combination With R-CHP for People With Certain Types of Previously Untreated Diffuse Large B-cell Lymphoma - Vimarsana News

FDA Approves Genentech's Polivy in Combination With R-CHP for People With Certain Types of Previously Untreated Diffuse Large B-cell Lymphoma

– Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma, an aggressive disease and the most common form of... | April 19, 2023

FDA Approves "Digital Pill" to Track Patients' Compliance with Psych Meds - Vimarsana News

FDA Approves "Digital Pill" to Track Patients' Compliance with Psych Meds

The FDA approved a psychotropic drug containing a sensor that transmits compliance information to doctors, sparking fear and controversy.

U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine - Vimarsana News

U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine

QULIPTA® now the first and only oral CGRP receptor antagonist approved to prevent migraine across frequencies, including episodic and chronic Expanded...

FDA Updates Opioid Analgesic Labeling to Help Guide Prescribing Decisions - Vimarsana News

FDA Updates Opioid Analgesic Labeling to Help Guide Prescribing Decisions

The FDA has updated the prescribing information for all opioid analgesics in order to provide additional guidance on how to safely prescribe these medications.

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses - Vimarsana News

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix) 16.04.2023 / 21:01 CET/CESTThe issuer is solely responsible for the content of this...